Skip to content

Search Results

Current Grantees

…Apoptotic Vulnerabilities in Ovarian Cancer Simon Gayther, PhD, Cedars-Sinai Medical Center iPSC Modeling of Ovarian Cancers in BRCA1 and 2 Mutation Carriers 2022 Grant Recipients Jen-Tsan Chi, MD, PhD, Duke…

Rucaparib Extends PFS in Ovarian Cancer

…with BRCA wild-type and loss of heterozygosity high, or LOH high, and the third group with BRCA wild-type and LOH low. Each group was treated with oral rucaparib twice per…

Prevention & Risk

…Genetic Risk Factors BRCA1 and BRCA2 Genetic Mutations Impact: Approximately 20% of ovarian cancers are hereditary, primarily due to BRCA mutations. Connection: Women with a history of breast cancer may…

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.